Y Intercept Hong Kong Ltd Buys 8,181 Shares of IDEXX Laboratories, Inc. $IDXX

Y Intercept Hong Kong Ltd increased its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 149.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,665 shares of the company’s stock after buying an additional 8,181 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in IDEXX Laboratories were worth $7,678,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of IDXX. SHP Wealth Management purchased a new position in IDEXX Laboratories during the 4th quarter worth $26,000. Virtus Advisers LLC bought a new stake in shares of IDEXX Laboratories in the 3rd quarter worth $26,000. Park Place Capital Corp purchased a new stake in shares of IDEXX Laboratories in the fourth quarter valued at about $29,000. WealthCollab LLC purchased a new stake in shares of IDEXX Laboratories in the second quarter valued at about $30,000. Finally, Caitong International Asset Management Co. Ltd bought a new position in shares of IDEXX Laboratories during the third quarter valued at about $36,000. 87.84% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on IDXX shares. Stifel Nicolaus cut their price target on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Wall Street Zen raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday, June 13th. Citigroup assumed coverage on IDEXX Laboratories in a research note on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 target price on the stock. Weiss Ratings raised IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, June 25th. Finally, UBS Group decreased their price target on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research report on Tuesday, April 28th. Seven research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $751.00.

IDEXX Laboratories Stock Performance

NASDAQ IDXX opened at $557.80 on Friday. The company has a market capitalization of $44.00 billion, a PE ratio of 41.08, a price-to-earnings-growth ratio of 3.05 and a beta of 1.55. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12. IDEXX Laboratories, Inc. has a 52-week low of $506.91 and a 52-week high of $769.98. The company has a 50-day simple moving average of $555.31 and a 200 day simple moving average of $609.16.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The firm had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.12 billion. During the same period in the previous year, the company earned $2.91 earnings per share. The company’s quarterly revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, research analysts predict that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.